PhoenixBio
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
PhoenixBio provides preclinical contract research services and products using its proprietary humanized liver mouse model to improve drug development translation.
Metabolic DiseasesInfectious DiseasesGenetic Disorders
Technology Platform
Proprietary chimeric mouse model (PXB-mouse®) with a humanized liver repopulated by human hepatocytes, and derived primary human hepatocytes (PXB-cells®), designed to mimic human liver biology for preclinical testing.
Opportunities
Growth is driven by increasing demand for predictive preclinical models in gene therapy, metabolic disease (MASH), and complex DMPK studies, as well as expansion of service offerings through global CRO partnerships.
Risk Factors
Key risks include competition from other humanized model providers, the long-term shift towards non-animal New Approach Methodologies (NAMs), and the operational and ethical complexities of a live-animal-based production model.
Competitive Landscape
Competitors include other humanized liver model providers like Yecuris Corporation. PhoenixBio differentiates itself through its claimed position as the most widely used model, high-volume production capability (100+ mice/week), and its established CMHL industry consortium.